Hyperfine Reaffirmed at Buy as Strong Q1 Momentum and Swoop V2 Demand Support Unchanged $2 Price Target

In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Hyperfine, with a price target of $2.00.

Marie Thibault has given his Buy rating due to a combination of factors, including Hyperfine’s stronger‑than‑expected Q1 performance and improving fundamentals. The company exceeded revenue expectations, delivered better gross margins, and confirmed its medium‑term growth outlook and cash burn targets, suggesting disciplined execution and a clear path toward scale.

Thibault also highlights rising demand for the next‑generation Swoop V2 system across hospitals, IDNs and neurology practices, with new international approvals and planned EU launch adding further upside. Pipeline expansion into new care settings, ongoing clinical studies that could support higher reimbursement, and published data on clinical and economic benefits all reinforce the growth story, supporting the unchanged $2 price target and Buy rating.

HYPR’s price has also changed dramatically for the past six months – from $1.100 to $1.730, which is a 57.27% increase.